

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY 5227

Maine Medical Association

P. O. BOX 280
BRUNSWICK, MAINE 04011
TELEPHONE 725-6414

Executive Director
DANIEL F. HANLEY, M.D.

Secretary-Treasurer
ESTHER M. KENKARD

February 3, 1969

Dear Doctor:

You may be aware of the FDA order to withdraw Mysteclin-F from the market due to the NAS/NRC panel's report on Mysteclin-F, indicating that they are not aware of evidence of proved efficacy in the prevention of disease due to monilia organisms, although suppression of growth of monilia may be accomplished.

- IF you believe Mysteclin-F has had a definite useful place among the antibiotics prescribed in your practice, particularly for those types of patients prone to candidal infections (women with a history of candidiasis, elderly patients, debilitated patients, diabetics, patients on corticosteroids, etc);
- IF your medical opinion is that spread of intestinal candida to cause candidiasis is a risk which in the indicated conditions should be considered in using antibiotic therapy;
- IF you feel that the combination contained in Mysteclin-F in your experience is convenient, useful, effective and of definite value in the care of your patients;
- IF you feel the FDA order to withdraw Mysteclin-F from availability for prescription use would create an unnecessary and inconvenient restriction on your prescribing freedom to the detriment of your patients -

Please forward your opinion to:

Herbert L. Ley, Jr., M.D.
Commissioner of Food and Drugs
Department of Health, Education
and Welfare
Washington, D.C. 20204

*In my experience I find that Mysteclin F
is very effective in Treach mouth. It
does a very good job where the penicillin
Tetracyclines fail. I would hate to
see it removed from the market
of course I don't use it for
all infection only the
ones I feel it is
indicated in.*

116th Annual Session, The Samoset, Rockland, Maine, June 15-17, 1969